West Japan Thoracic Oncology Group

Quick facts

Phase 3 pipeline

• Cisplatin+Vindesine+MMC/ concurrent radiation · Oncology
  This combination uses three chemotherapy agents (cisplatin, vindesine, and mitomycin C) alongside radiation therapy to damage cancer cell DNA and inhibit cell division through multiple mechanisms.
• Irinotecan+Carboplatin/concurrent radiation · Oncology
  Irinotecan and carboplatin are chemotherapy agents combined with concurrent radiation therapy to damage cancer cell DNA through multiple mechanisms while radiation directly destroys tumor tissue.
• Paclitaxel+Carboplatin/concurrent radiation · Oncology
  Paclitaxel and carboplatin chemotherapy combined with concurrent radiation therapy work synergistically to damage cancer cell DNA and inhibit microtubule function, while radiation enhances cytotoxic effects.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• West Japan Thoracic Oncology Group portfolio CI brief
• West Japan Thoracic Oncology Group pipeline updates RSS